Shields J A, Shields C L, Parsons H, Giblin M E
Ocular Oncology Service, Wills Eye Hospital, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107.
Arch Ophthalmol. 1990 Feb;108(2):205-8. doi: 10.1001/archopht.1990.01070040057030.
We treated selected patients with retinoblastoma with xenon arc photocoagulation between February 1974 and August 1987. Of 790 individual tumors in 410 affected eyes, 45 were treated by this technique. Overall photocoagulation alone was successful in eradicating 76% of the tumors, while in 24% of the tumors additional treatment with cryotherapy, plaque radiotherapy, external beam radiotherapy, or enucleation was necessary. In cases where the tumor was less than or equal to 3.0 mm in diameter and 2.0 mm in thickness and was confined to the sensory retina, without seeding into the adjacent vitreous, tumor destruction was achieved with photocoagulation. The mean number of photocoagulation sessions needed for complete tumor regression was 2.5. Photocoagulation alone was generally unsuccessful for tumors greater than 4.5 mm in diameter and 2.5 mm in thickness, and supplemental treatment with other modalities was often necessary in such cases. Based on observations in these patients, we point out certain misconceptions regarding photocoagulation of retinoblastomas and define our current indications and contraindications for this treatment modality.
1974年2月至1987年8月期间,我们对选定的视网膜母细胞瘤患者进行了氙弧光凝治疗。在410只患眼中的790个独立肿瘤中,有45个肿瘤采用了该技术治疗。总体而言,单纯光凝成功根除了76%的肿瘤,而24%的肿瘤需要额外进行冷冻疗法、敷贴放疗、外照射放疗或眼球摘除术。对于直径小于或等于3.0毫米、厚度小于或等于2.0毫米且局限于感觉视网膜、未播散至相邻玻璃体的肿瘤,通过光凝可实现肿瘤破坏。肿瘤完全消退所需的平均光凝次数为2.5次。对于直径大于4.5毫米、厚度大于2.5毫米的肿瘤,单纯光凝通常不成功,在这种情况下通常需要采用其他方式进行补充治疗。基于对这些患者的观察,我们指出了关于视网膜母细胞瘤光凝的某些误解,并明确了我们目前对这种治疗方式的适应证和禁忌证。